Does Osteoporosis Treatment Reduce Overall Mortality in Addition to Fracture Risk?

According to a recent meta-analysis, no significant association was observed between pharmacotherapies used for osteoporosis treatment and mortality rate, despite previous studies suggesting the treatments, particularly bisphosphonates, lower overall mortality. To investigate this association, study authors searched various databases and conference abstracts for randomized placebo-controlled studies in which drug therapies were evaluated for a year…

Higher Intensity Therapy With Simvastatin-Ezetimibe May Benefit Elderly Patients After ACS

According to the results of a secondary analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), treatment with simvastatin-ezetimibe appears to be beneficial for patients ≥75 years old with stabilized acute coronary syndrome (ACS), compared with simvastatin alone.   IMPROVE-IT was a randomized, double-blind, multicenter study that evaluated the outcomes and risks…

Ezallor capsule

FDA Approves Sprinkle Formulation of Rosuvastatin

The Food and Drug Administration (FDA) has approved a new sprinkle formulation of rosuvastatin, an HMG Co-A reductase inhibitor.  Ezallor Sprinkle (Sun Pharma) is indicated for the treatment of adult patients with: hypertriglyceridemia as an adjunct to diet; primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet; and homozygous familial hypercholesterolemia to reduce LDL-C,…

Dosages for the Elderly

Dosing considerations for elderly patients: renal function, drug severity, drug distribution, polypharmacy, and hepatic function.